C30 LUNG CANCER SCREENING: WHO, WHY, WHERE, AND HOW MUCH: The Clinical Benefit And Cost-Effectiveness Of Adding A Smoking Cessation Program To A Simulated Lung Cancer Screening Program In Saskatchewan, Canada

C30 LUNG CANCER SCREENING: WHO, WHY, WHERE, AND HOW MUCH: The Clinical Benefit And Cost-Effectiveness Of Adding A Smoking Cessation Program To A Simulated Lung Cancer Screening Program In Saskatchewan, Canada

Over the 20-year study period in Saskatchewan, screening could identify 470 more lung cancer cases, save 570 quality adjusted life years (QALY), and avert 230 lung cancer deaths at an incremental cost of $71.5 million ($125,000/QALY). Discussion and Conclusion Even at a low probability of smoking ce...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Hauptverfasser: Bethune, R, Wu, L, Goodridge, D, Hergott, C, Osgood, N, Manns, B, Tian, Y, Sherin, T, Penz, E
Format: Artikel
Sprache:eng
Schlagworte:
Cost analysis
Lung cancer
Medical screening
Smoking cessation
Success
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Over the 20-year study period in Saskatchewan, screening could identify 470 more lung cancer cases, save 570 quality adjusted life years (QALY), and avert 230 lung cancer deaths at an incremental cost of $71.5 million ($125,000/QALY). Discussion and Conclusion Even at a low probability of smoking cessation success, lung cancer screening in Saskatchewan becomes more effective and cost-effective with an adjunct smoking cessation program.
ISSN:1073-449X
1535-4970